This is the Future of the Medical Industry
We are witnessing a seismic shift away from the traditional acute care to modern chronic solutions.
If you look closely, CES 2020 this year was dominated by five key technologies. One of them is digital health, as we have noted before with PiCO GO as a digital therapeutics, a key technology that can lead to disruptive change and shake the paradigm of the existing market in the future.
This is important because the nature of our healthcare is rapidly modernizing. In the past, the focus was on treating acute diseases with medications and surgeries but today, most illnesses, specifically chronic diseases like obesity and diabetes, come as a result of poor lifestyle choices such as the lack of exercise or eating too much unhealthy food.
Digital health is slowly growing and has gained recognition from many health organizations including the FDA. The use of technology and the internet is not only changing the way we communicate, but also providing innovative ways for us to monitor our health and well-being and giving us greater access to information.
These digital health products, or digital therapeutics as we’ve envisioned with PiCO GO, use that innovation to provide patients with a low-cost intervention and personalization to treat and manage their diseases. Its purpose is to spur lifestyle changes and have been proven to reduce inefficiencies, reduce costs, and increase quality.
FDA’s role in digital health is particularly significant, as they help revolutionize the convergence of medical devices with connectivity and consumer technology. Additionally, they provide clarity to the many digital health fields that have sprung up like wireless medical devices, telemedicine, and software as a medical device (SaMD).
FDA Approves Abbott Proclaim XR
The latest example of the growing and acceptance of DTx, Abbott, which was featured at CES 2020, recently received approval from the FDA for its Proclaim XR innovation, a recharge-free neurostimulation system for people living with chronic pain. This approval marks a breakthrough for patients with spinal cord pain and will be a prelude to the entry of more DTx into the market in the coming years.
Where PiCO GO Fits in This?
At Brilliant & Company, our goal is to always create a healthier life. PiCO Home, released late last year, was our foray into the smart home market, and its integration with smart AI speakers like Amazon Alexa gives users a unique, interactive, and fun way to monitor their environment.
That said, we plan to launch PiCO GO this year, a revolutionary product that combines all the features and technology from PiCO Home, to herald our entry as a digital therapeutics for pediatric asthma patients, into the medical market.
As the momentum builds for DTx, we are excited about what the future holds as we embark onto another successful year for Brilliant & Company.
To inquire more about Brilliant & Company, please do not hesitate to drop us a line:
- CEO / Ryan Yun / ryan.yun@brilcom.com
- Global Marketing Manager / Steve Tan / steve.tan@brilcom.com
